Psychedelic Alpha
@Psyched_Alpha
Followers
20K
Following
3K
Media
788
Statuses
7K
Empowering a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact in psychedelic medicine and beyond.
Joined April 2020
Introducing Pα+. We're launching a reader-supported model for our more analysis-focused content such as Psychedelic Bulletins, deep dives and interviews. Read the announcement, and subscribe at a discounted launch rate, here:.
18
7
22
Pα+ Psychedelic Bulletin #208: . - Psychedelic CEOs’ FDA Wish-List. - APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published. - Cybin Ousts Drysdale. - more.
psychedelicalpha.com
Psychedelic CEOs’ FDA Wish-List • APA Division 56 President Jessica Punzo on Psychologists and Psychedelics • Compass’ Phase 2 PTSD Study Published • Cybin Ousts CEO Doug Drysdale •
2
0
4
Read FDA's Complete Response Letter to Lykos Therapeutics' MDMA for PTSD Application.
4
1
7
BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL).
psychedelicalpha.com
FDA has published its complete response letter (CRL) to Lykos Therapeutics, citing durability, safety, and bias concerns in rejecting MDMA therapy for PTSD. Here, we very briefly unpack the letter.
4
7
22
RT @MichaelHaichin: functionally unblinded.mystically guided.chakras aligned-ed.sponsor's delighted.rigour subsided.results derided.placebo….
0
3
0
Sensorium Therapeutics has raised a $25M Series A extension, led by Mission BioCapital, Hatteras Venture Partners, Mockingbird Capital Partners, and Dolby Family Ventures. Read more:
1
1
0
The U.S. Drug Enforcement Administration (DEA) has transmitted a petition to move psilocybin to Schedule II to the Department of Health and Human Services (HHS). Read more:
21
32
114
The Psychedelic Alpha store is now open. Whether you’re navigating Schedule I bureaucracy, debating 5-HT2A receptor binding profiles, or want to let others know your critical period is open, there might just be something for you. Explore now:
0
2
9
MDMA drug developer Lykos Therapeutics has changed its name to Resilient Pharmaceuticals, Inc., Psychedelic Alpha understands. More:
1
2
6
Last Week in Psychedelics. Keep tabs with our News Feed:
0
2
5
Pα+ Psychedelic Bulletin #207. - Lykos Rebrands to Resilient. - Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision. - AbbVie-Gilgamesh Deal Viewed as Validation. - Psilocybin Rescheduling Petition Heads to HHS. - Much, much more.
psychedelicalpha.com
Lykos Therapeutics Rebrands to Resilient Pharmaceuticals • Pharma Pushes Back on Norway’s Off-Label Ketamine Decision • AbbVie–Gilgamesh Deal Viewed as Validation for Short-Acting Psychedelics •
0
0
10
Experts react to Norway's decision to reimburse generic ketamine for use in treatment-resistant depression. Hear from Lars Lien and Lowan Stewart in our coverage:
1
0
7
July 2025 Psychedelic Patent Update. Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio.
psychedelicalpha.com
Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio.
0
0
2
RT @Josh__Hardman: Psychedelic stocks open higher on the news of AbbVie's $1.2bn acquisition of a Phase 2 psychedelic candidate. https://t.….
0
5
0
AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B. We take a closer look at the acquisition, what it might tell us about big pharma's interest in the field, and what it might mean for the broader crop of psychedelic drug developers.
psychedelicalpha.com
AbbVie is set to buy Gilgamesh Pharmaceuticals’ lead candidate, GM-2505 (bretisilocin), in a deal worth up to $1.2bn. Here, we take a closer look at the acquisition, what it might tell us about big…
2
7
26
BREAKING: Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression. In a world-first move, 🇳🇴 approves national reimbursement for off-label use of generic ketamine in treatment-resistant depression, effective immediately.
psychedelicalpha.com
This morning, in a world-first move, Norwegian regulators approved national reimbursement for the off-label use of generic ketamine in treatment-resistant depression. Here, we break the news…
2
4
19
Sensorium raises $25M to test succulent-derived drug for anxiety.
endpoints.news
Sensorium, a startup founded by scientists from Mass General and Harvard in 2021 to look for new brain drugs from plants and fungi, has raised a $25 million series A extension, the company told...
0
0
0
Discover Psychedelic Alpha like never before by using our new AI search tool, trained exclusively on in-house content and data. Use any search bar on our website to get started, or visit our dedicated webpage:
1
1
6
Reunion Neuroscience's CEO, Greg Mayes, spoke to Psychedelic Alpha about his company's positive Phase 2 results of RE104 (a 4-OH-DiPT prodrug) for postpartum depression. Read more:
0
0
1
BREAKING: Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression. Read our Deep Dive coverage, including a discussion with company management, now.
psychedelicalpha.com
This morning, Reunion Neuroscience posted positive topline results from its Phase 2 study of RE104, its 4-OH-DiPT prodrug, in postpartum depression (PPD). We spoke with Reunion leadership to dig...
0
3
8
One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect. @Josh__Hardman spoke with a former Lykos exec, MAPS founder Rick Doblin, members of the FDA Advisory Committee that panned the program, and others for this deep-dive.
psychedelicalpha.com
One year after FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD application, insiders and observers reflect on what went wrong and what comes next. This in-depth…
3
5
10